CDT Equity Partners with QIMA to Explore Tapinarof Combinations for Psoriasis and Vitiligo
Event summary
- CDT Equity Inc. has partnered with QIMA Life Sciences to evaluate novel tapinarof combinations for psoriasis and vitiligo.
- Initial studies will focus on tapinarof (VTAMA®), approved for plaque psoriasis and atopic dermatitis in the US and Japan.
- The partnership aims to develop a second-generation tapinarof product with increased efficacy and patient benefits.
- CDT will also investigate the potential of tapinarof combinations in vitiligo, a market projected to reach $6.6 billion by 2030.
The big picture
CDT Equity's partnership with QIMA Life Sciences underscores the growing trend of leveraging patient-derived tissue for preclinical dermatology research. This strategic move aims to enhance the efficacy of tapinarof, a top-performing branded topical treatment, and tap into the expanding vitiligo market. The collaboration highlights the importance of clinically relevant data in accelerating drug development and securing licensing opportunities.
What we're watching
- Combination Therapy Potential
- How the novel tapinarof combinations will perform in psoriatic patient skin and whether they can expand VTAMA®'s market.
- Vitiligo Market Opportunity
- The pace at which CDT can develop and commercialize tapinarof combinations for vitiligo, a market with significant unmet needs.
- Partnership Outcomes
- Whether the collaboration with QIMA Life Sciences will yield clinically relevant data to attract potential license partners.
Related topics